GSK » Topics » GSK1838262

This excerpt taken from the GSK 6-K filed Feb 7, 2008.
GSK1838262 – results from a second positive phase III trial demonstrating the potential of ’262 as a treatment for Restless Legs Syndrome were announced last month. Additional phase III data are expected during the first quarter of 2008, with an FDA filing planned for the third quarter.

Rezonic – positive data from two phase III trials in chemotherapy-induced nausea and vomiting were received in 2007 and GSK expects to file Rezonic for use in this indication and for the treatment of postoperative nausea and vomiting in 2008.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki